Related Experiment Video
Updated: Feb 24, 2026
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Effective apatinib treatment of pleomorphic liposarcoma: A case report
Peng Yan1, Mei-Li Sun, Yu-Ping Sun
1Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Rationale:
Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease.
Patient Concerns:
We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy.
Diagnoses:
The patient was diagnosed as having PLS by biopsy.
Interventions:
After a failed chemotherapy, apatinib started to be taken orally 425 mg per day.
Outcomes:
This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS).
Lessons:
In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
06:11Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique
Published on: May 2, 2025